Capella Imaging, LLC, is a biogenerator company focused on the development of diagnostic imaging agents to support unmet medical needs. Capella Imaging has developed a fibrin-targeted diagnostic imaging agent for cardiac imaging. FibroScint  (Tc-99m F4A] is a fibrin-targeted, peptide compound labeled with the radioisotope technetium-99m (Tc-99m) for SPECT imaging. If successfully developed and approved, it may have potential applications across multiple cardiovascular conditions such as thrombus (blood clots) associated with left ventricular assist devices (LVADs), deep vein thrombosis, pulmonary embolism and acute coronary syndrome.